Researchers at Yale University, Massachusetts General Hospital, the Weizmann Institute of Science, and the University of Miami have identified two distinct patterns of tumour evolution in IDH-mutant glioma. This incurable brain cancer most commonly affects adults in their 30s and 40s. The findings, published in Nature, shed light on how these tumours shift from treatment-sensitive states at initial diagnosis to treatment-resistant states at recurrence.
The study analysed molecular data from tumours collected across multiple time points from 35 patients with IDH-mutant glioma. Rather than relying solely on bulk tumour sequencing, the team integrated DNA sequencing, single-cell RNA sequencing, and single-cell chromatin accessibility profiling. This combination allowed the researchers to track genetic changes over time, measure gene activity in individual tumour cells, and identify which regions of the genome were active, linking specific genetic events to the cellular states that emerge as tumours recur.
The analysis revealed a clear divergence in recurrence patterns. In some patients, tumours remained relatively stable, with limited genetic and cellular change. In others, recurrent tumours acquired new genetic alterations and transitioned towards more aggressive cellular programmes, including stem cell-like and highly proliferative cell states, alongside changes in the tumour microenvironment characterised by immune-suppressive cell populations. This latter pattern bore close resemblance to features observed in glioblastoma, the most lethal form of brain cancer.
The group showing substantial genetic change at recurrence demonstrated reduced sensitivity to treatment, potentially explaining why certain tumours become increasingly difficult to manage following initial therapy. The authors emphasise that current treatments remain beneficial and that this work aims to identify earlier when and why tumours lose treatment sensitivity, to inform more effective subsequent therapeutic strategies.
Source: Johnson KC et al. Acquired genetic and cell-state changes in IDH-mutant glioma progression. Nature (2026). DOI: 10.1038/s41586-026-10612-6.
